The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche's Rituxan.
As we recently reported, the Institute of Medicine proposed changing the name of chronic fatigue syndrome to systemic exertion intolerence disease (S.E.I.D.) in an attempt to challenge stigma and misunderstanding about the condition. But will a new name be enough to lead doctors to take diagnosis and treatment more seriously, or will it continue to […]
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.